CN106520599A - Lactobacillus reuteri and applications - Google Patents
Lactobacillus reuteri and applications Download PDFInfo
- Publication number
- CN106520599A CN106520599A CN201610937700.2A CN201610937700A CN106520599A CN 106520599 A CN106520599 A CN 106520599A CN 201610937700 A CN201610937700 A CN 201610937700A CN 106520599 A CN106520599 A CN 106520599A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- culture
- bacterium
- cctcc
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 53
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 53
- 101100207366 Curvularia clavata TR02 gene Proteins 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 208000004232 Enteritis Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 30
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 9
- 208000002551 irritable bowel syndrome Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- 239000012531 culture fluid Substances 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229960002433 cysteine Drugs 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 238000007817 turbidimetric assay Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- -1 phosphoric acid hydrogen Chemical class 0.000 description 1
- 230000005622 photoelectricity Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses lactobacillus reuteri. The classification name of lactobacillus reuteri is lactobacillus reuteri TR02, the lactobacillus reuteri TR02 is preserved in the China Center for Type Culture Collection (CCTCC), and is assigned with the accession number of CCTCC No. M 2016546, and the preservation date is Oct 10, 2016.The invention further discloses applications of lactobacillus reuteri in preparing medicines for treating gastrointestinal diseases.
Description
Technical field
The invention belongs to microbial technology field, more particularly to a kind of Lactobacillus reuteri and its preparing treatment gastrointestinal tract
Application in the medicine of disease.
Background technology
Ulcerative colitiss (UC), cryptitiss and sieve engler's disease are the main Types of inflammatory bowel (IBD), the inflammatory bowel
Disease is characterised by the chronic inflammatory disease in intestinal.Clinical symptoms be suffer from diarrhoea, suffer from abdominal pain, occasionality hemorrhage of rectum, lose weight, it is tired and
Sometimes generate heat.Although can occur at any age, IBD is most commonly in the adult of teenager and youth, so these people can
The development that can be postponed and dwarfing grow.Data shows that annual U.S. UC prevalences are 2,00/,100,000 people, treat the flower of UC
Take at 1 to 1.5 hundred million dollar or so, by the end of 2012, UC patient populations were 2.5 times in 2000, and relapse rate is up to 72%；Closely
The number of patients of Nian Lai China UC is in obvious ascendant trend.
Medically, by reducing inflammation and thereby controlling gastrointestinal tract symptom treating IBD.But, at present still can not be
Medically cure IBD.The Clinical course of IBD has very big difference, with patient slightly to moderate symptom without the need for hospitalization, but
It is that the patient of 10-15% can occur the serious process of the disease, and which is followed by surgical operation, colectomy in many cases
Art can eliminate UC, but can reduce quality of life and increase the risk of complication.
Medicine for treating IBS has been popularized, although their effect in clinical trial are little, and
Their Clinical practicability is limited by adverse side effect, and available medicine includes：Using 5- aminosalicylic acid (5-
ASA), corticosteroid and immunoregulation medicament.5-ASA is usually used carries out the slight long-term treatment to moderate IBD symptom, and
Corticosteroid and immunoregulation medicament are used for treating serious symptom；Diarrhoea or stomachache go out as the side effect of 5-ASA
It is existing, and the life-time service Jing of corticosteroid often shows serious side effect, including sclerotin mitigation, infection, diabetes, muscle
Become thin and psychiatric disturbance；Immunoregulation medicament can suppress immune system, and this can control IBD symptoms.But, the immunity of generation
Impaired state can make patient susceptible's numerous disease.Serotonergic medicament has shown the effect of the overall symptom to IBS,
But, their application has seriously been limited with regard to the worry of safety recently.
Probiotic bacteria is defined as that " microorganism living, which can be played beyond intrinsic basis after taking in given number
Health benefits beyond nutrition " (Araya M. et al., 2002；Guarner F. et al., 1998).From the several of Bifidobacterium
It is probiotic bacteria to plant lactic acid bacteria and kind, this hint, it has already been proven that they can promote specific health effect.Probiotic bacteria must is fulfilled for
The several requirements relevant with no toxicity, viability, attachment and beneficial effect.However, existing probiotic bacteria is to treating enteritis effect
It is not good.
The content of the invention
Goal of the invention：The first object of the present invention is to provide a kind of Lactobacillus reuteri.
The second object of the present invention is to provide a kind of Lactobacillus reuteri in the medicine for preparing treatment gastroenteropathy
Application.
The third object of the present invention is the application for providing a kind of Lactobacillus reuteri in the medicine for preparing treatment enteritis.
Technical scheme：In order to solve above-mentioned technical problem, the technical solution adopted in the present invention is：A kind of Luo Yishi breasts bar
Bacterium, its Classification And Nomenclature are Lactobacillus reuteri (Lactobacillus reuteri) TR02, in China typical culture collection
The heart (abbreviation CCTCC) preservation, depositary institution address：Wuhan City, Hubei Province Wuchang District Wuhan University, postcode is 430072, its
Deposit number is：CCTCC No.M 2016546, preservation date are on October 10th, 2016.
The physiologically active feature of Lactobacillus reuteri (Lactobacillus reuteri) TR02 is as follows：
Lactobacillus reuteri (Lactobacillus reuteri) TR02 bacterium colonies on MRS culture medium flat plates are less,
Milky, diameter 1-2mm, surface are smoothed, and edge is relatively regular.
Lactobacillus reuteri (Lactobacillus reuteri) the TR02 thalline are shaft-like, Gram-positive,
Spore is not formed, lactic acid, amphimicrobian is produced.
The 16SrDNA sequences of Lactobacillus reuteri are as shown in SEQ ID No.1.Surveyed 16SrDNA sequences are passed through into BLAST
Compare, be identified as Lactobacillus reuteri (Lactobacillus reuteri).
Described Lactobacillus reuteri (Lactobacillus reuteri) TR02 is answering in antibacterials are prepared
With.
Described Lactobacillus reuteri (Lactobacillus reuteri) TR02 is to prepare treatment gastroenteropathy
Application in medicine.
Described Lactobacillus reuteri (Lactobacillus reuteri) TR02 is in the medicine for preparing treatment enteritis
Application.
Have particular application as：Lactobacillus reuteri (Lactobacillus reuteri) TR02 is inoculated in into fermentation medium
In, in 35-39 DEG C of bottom fermentation culture 8-16 hour, the fermentation liquid for obtaining is used as applying microbial inoculum.
The formula of heretofore described fermentation medium is：1000mL distilled water, peptone 10g, glucose 20g, yeast
Powder 9g, sodium acetate 5g, dipotassium hydrogen phosphate 2g, Triammonium citrate 2g, cysteine 0.5g, magnesium sulfate 0.2g, manganese sulfate 0.05g,
Tween 1ml, pH5.5-6.5.
Beneficial effect：Compared with prior art, it is an advantage of the invention that：
(1) Lactobacillus reuteri (Lactobacillus reuteri) TR02 that the present invention is provided has to various pathogen
There is inhibitory action；Model of action variation to pathogen；Reproduction speed is fast；Being capable of artificial culture, it is easy to operate, it is easy to production
Using；The advantages of high-output stress-resistance.
(2) present invention is provided Lactobacillus reuteri (Lactobacillus reuteri) TR02 condition of culture is simple, send out
The ferment time is short, easy preservation, is suitable to industrialized production, with good development prospect.
Description of the drawings
Bacterium colony figures of the Fig. 1 for Lactobacillus reuteri (Lactobacillus reuteri) TR02.
Bacterium colony enlarged drawings of the Fig. 2 for Lactobacillus reuteri (Lactobacillus reuteri) TR02.
Fig. 3 is strain first batch Evaluation of Functional growth curve.
Fig. 4 is strain second lot Evaluation of Functional growth curve.
Fig. 5 is the acidproof experimental result picture of bacterial strain.
Fig. 6 is the weight relation curve of lactic acid bacterium number and enteritis mice.
Fig. 7 is the colon lengths relation curve of lactic acid bacterium number and enteritis mice.
Fig. 8 is enteritis mice slice map before and after treatment.
Fig. 9 is Lactobacillus reuteri TR02 and Candida albicanss culture fluid culture fungistatic effect figure.
Specific embodiment
Elaborate Lactobacillus reuteri of the present invention (Lactobacillus reuteri) TR02's with reference to experimental example
Using.
In the embodiment of the present invention, representative meaning of below abridging is respectively：
MRS：Lactic acid bacteria culture medium
DSS：Dextran sulfate sodium
Sulfasalazine sulfasalazines
Microcapsule microcapsules
The separation of 1 bacterial strain of embodiment
1st, strain and culture medium and condition of culture
(1) bacterium source
From certain military region health soldier's feces of China.
(2) culture medium
Plating medium：1000mL distilled water, peptone 10g, glucose 20g, yeast powder 9g, sodium acetate 5g, phosphoric acid hydrogen
Dipotassium 2g, Triammonium citrate 2g, cysteine 0.5g, magnesium sulfate 0.2g, manganese sulfate 0.05g, tween 1ml, agar powder 15-20g,
pH5.5-6.5。
2nd, the separation and identification of bacterial strain
(1) separation of bacterial strain
Proper amount of fresh feces are taken in glove box after sterilized process in advance and is placed in the aseptic examination for being loaded with aseptic culture medium
Guan Zhong, fully shaking are vortexed and mix；
The feces solution for mixing is vortexed as stock solution with above-mentioned fully shaking, ten times of gradient dilutions is done to suitable gradient, is taken 100
μ l are spread evenly across in MRS+0.05% cysteine solid plate culture medium, are subsequently taken out and are placed in anaerobic jar, 37 DEG C of anaerobism
Overnight incubation.
On next day visible flat board, length has the bacterium colony of form different sizes, special with reference to Lactobacillus reuteri colonies typical form
Levy, some representational bacterium colonies of picking make secondary line purification process, flat board anaerobism activates 1 day, obtains culture, subsequently do bacterium
Strain identification.
(2) identification of bacterial strain
Gram’s staining Morphological Identification：
A, smear：Sterilized microscope slide is taken in laboratory table, is marked with marking pen on slide, be easy to observation, with
Afterwards slide is inverted, and then 10 μ l physiological saline solution is drawn with pipettor and is uniformly coated at mark, is chosen with liquid-transfering gun then
Take pure culture to be uniformly dissolved in normal saline, coated face is unsuitable excessive.
B, drying：Specimen is faced upwards, the both sides of hand-held microscope slide one end, carefully on alcohol burner, eminence adds slightly
Heat, makes moisture evaporation, but be sure not it is long against flame or heat time heating time, in case specimen is baked withered and is deformed.
C, fixation：It is fixed usually to utilize high temperature, one end of hand-held microscope slide, specimen upwards, at the alcohol burner flame as early as possible
Back and forth through 2-3 time, altogether about 2-3 second kinds, and touch skin with the heating of the microscope slide back side frequently unconsciously are scalded to be advisable excessively and (are not surpassed
Cross 60 DEG C), place after cold, dyeed.
D, just dye：The Deca ammonium oxalate crystal violet 1-2 drops on smear thin film, make dyeing liquor cover smear, dye about 1min.
E, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
F, mordant dyeing：About 300ul iodine solutions are drawn with 100-1000ul liquid-transfering guns to drop on smear thin film, is covered dyeing liquor and is applied
Piece, dyes about 1min.
G, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
H, decolouring：Tilting microscope slide, 95% ethanol decolorization of Deca, not showing purple to the ethanol for flowing out, about take
20-30S, is washed immediately.
I, redye：The Deca husky of common dye dye liquor 1-2 drops on smear thin film, make dyeing liquor cover smear, dye about 1min.
J, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
K, drying, observation：Water droplet is sopped up with absorbent paper, treats that sample slice is done under rearmounted microscope, use low power sem observation, found
Immersion oil being dripped after purpose thing on slide, the form and color of antibacterial being observed with oil mirror, purple is gram positive bacteria, red
Color is gram negative bacteria.
As a result show：The bacterial strain is gram positive bacteria.
The measure of 16S rRNA sequences：
The PCR primers that use of amplification of 16S rRNA genes be general antibacterial primer 8F (5 '-
CACGGATCCAGAGTTTGAT (C/T) (A/C) TGGCTCAG-3 ') and 1510R (5 '-GTGAAGCTTAGGG (C/T)
TACCTTGTTACGACTT-3 ') product entrusts qualified third party's laboratory to carry out sanger sequencings.Using BLAST algorithm
Sequence and 16S rRNA genes are compared in GenBank data bases, adjacent tree is set up using MEGA4.0 programs.
BLAST analysis shows TR02 bacterium are sufficiently close to Lactobacillus reuteri (99% affinity).
Embodiment 2
(1) strain Evaluation of Functional
A. the measure of growth curve and each monitoring point pH value
1. labelling
Take 11 aseptic Boiling tubes, with marking pen indicate respectively incubation time, i.e., 0,2,4,6,8,24h.
2. it is inoculated with
Proceeded to 5mL aseptic straws absorption 2.5mL TR02 incubated overnight liquid (culture 8-16h) respectively and fill 50mL MRS+
In the triangular flask of 0.05% cysteine culture fluid, 11 nothings that 5mL mixed liquors are put into above-mentioned labelling after mix homogeneously, are taken respectively
In bacterium Boiling tube.
3. cultivate
Vaccinated test tube is put into quiescent culture in 37 DEG C of incubators, respectively culture 0,2,4,6,8,24h, will be indicated corresponding
The test tube of time takes out, and stores in putting refrigerator immediately, and last is with its optical density value of turbidimetric assay.
4. turbidimetric assay
Make blank with nonvaccinated MRS+0.05% cysteine culture medium, photoelectricity ratio is carried out from 600nm wavelength
Turbid measure, starts sequentially determining from the early culture fluid for taking out, the culture fluid MRS+0.05% cysteine big to cell density
Fluid medium is determined after suitably diluting so as to which optical density value is again within 0.1～0.65 (before determining OD values, by training to be determined
Nutrient solution vibrates, and is uniformly distributed cell).
The measure of 5.pH values
Remaining culture liq determines pH value.
B. ascites
1. prepared by bacteria suspension
Culture fluid is made by the appropriate bacteria suspension of concentration with physiological saline solution.
2. microscopy studio
Before sample-adding, microscopy is carried out to the studio of counting chamber first, if there is dirt, need cleaning, can just carry out after drying up
Count.
3. product are loaded
By cleaning dry blood cell counting plate covered, then with aseptic capillary burette by the culture fluid for shaking up by
Coverslip edge drips a droplet, allows bacterium solution to lean on capillary osmosis automatically into studio along gap, and general technology room can be filled
Full bacterium solution.
Bacterium solution will be first shaken up during sampling；During sample-adding, studio can not have bubble to produce.
4. microscopic counting
Static 5min after sample-adding, is then placed in blood cell counting plate on microscope carrier, first finds skill with low power lens
Art room position, then changes high power lenses into and is counted.
The power for adjusting microscope light is appropriate, should not be partial to one for being also noted that with the microscope of illuminator daylighting
It is difficult to see studio's grid line in side, the otherwise visual field, or only sees vertical line or only see horizontal line.
If finding before counting, bacterium solution is too dense or too dilute, counts after need to readjusting dilution factor, general sample dilution again
It is required that 5～10 thalline are there are about in per little lattice is advisable.Each studio selects 5 middle lattice (in optional 4 angles and central one
Lattice) in thalline counted.Above the general number of elements of thalline on ruling and on right side bearing.Counting sample will be from
The meansigma methodss that Liang Ge studios fall into a trap are calculating the bacteria containing amount of sample.
5. blood cell counting plate is cleaned
After finishing, blood cell counting plate is rinsed well with water on faucet, be sure not to be scrubbed with hard thing, after washing
Voluntarily dry or dried up with hair-dryer.Microscopy, whether observation is interior per little lattice residual thalline or other precipitate.If unclean,
Then necessary repeated washing is to clean.
Two batch strain Evaluation of Functional result collimations are preferable (being shown in Table 1, table 2, Fig. 3 and Fig. 4), growth curve result table
Bright TR02 bacterium are in 0～4h in laundering period, 4～8h and are in exponential phase, and 8～12h is in plateau, enters after 12h
Enter phase of decline；With growth curve in both diametrically opposite situation, culture terminal pH is 4.44 to pH curves.
Terminal culture fluid Jing microscopic counts result is 3.54 × 108cfu/ml。
1 batch of table, one strain Evaluation of Functional
2 batch of table, two strain Evaluation of Functional
(2) the acidproof experiment of bacterial strain
Strains tested is inoculated in MRS+0.05% cysteine hydrochloride fluid mediums, activation culture 24h, with
5% inoculum concentration is added to two parts with (it is blank that pH is 6.2 culture medium in the MRS culture medium that hydrochloric acid tune pH is 2.5 and 6.2
Control).First part is used sterile saline gradient dilution, is taken 100 μ L of diluent and is inoculated into MRS flat board coated plates, is placed in 37 DEG C, training
Foster 48h, carries out colony counting.After second part 37 DEG C process 3h, then sterile saline gradient dilution is used, take 100 μ L of diluent
MRS flat board coated plates are inoculated into, 37 DEG C of culture 48h are placed in, are carried out the viable count of colony counting, i.e. 3h, and calculate lactic acid bacteria
Survival rate：Survival rate (%)=(viable count of the viable count/0h of 3h) × 100.
3h is cultivated under pH6.5 and pH4.5 environment from table 3 and Fig. 5, TR02 and has no appreciable impact, and in pH3.0 bars
Growth under part is affected, and shows that TR02 can be tolerated under pH4.5 environment.
3 bacterial strain acid resistance test result of table
3 experiment in vivo of embodiment
1. the induction of colitis and treatment
With feeding C57BL/6 type mices of the solution containing 2.5%DSS (molecular weight 36-50KDa) (1-7 days), to induce colon
Scorching model mice；Matched group then feeds water.In subsequent 10 days, the oral water of difference, lactic acid bacteria (embedding 0.9*109、1.2*
109、2.4*109, do not embed 2.4*109) and willow nitrogen Huang amine pyridine (0.5g/kg).
Weigh in daily, in observation stool in mice viscosity and feces and at anus, whether have blood.Calculate disease activity
Index (DAI).In short, being calculated by following parameter：
A) diarrhoea (0 point=normal, 2 points=light feces, 4 points=watery diarrhea)；
B) blood courage (0 point=no bleeding, 2, slight bleeding, 4 points, massive hemorrhage).
The 10th day after inducing colitis, animal is put to death, take out colon, and colon's piece is prepared for analyzing in vitro.
It is in order to carry out histologic analysis, a part for colon is fixed in 10% formalin, and be embedded in paraffin.According to mark
H＆E is to section statining for quasi-project.
The Histological evaluation of the section of colon of H＆E dyeing is classified as follows：0, NIP sign；1. low leukocyte infiltration；2.
Moderate leukocyte infiltration；3. high leukocytic infiltration, moderate fibrosis, high vessel density, colon wall thickening, moderate goblet cell are damaged
Become estranged the focal loss and 4. transmurals infiltration of crypts, a large amount of losses of goblet cell, the diffusivity of extensive fibrosiss and crypts
Loss.Histological score is carried out by pathologist.
It is from Fig. 6,7,8, as the increase of lactic acid bacterium number improves significantly to the body weight of enteritis mice, right
The colon lengths of enteritis mice improve significantly, and enteritis mice is compared with the section of normal mouse, and goblet cell is gradually
Reduce, inflammatory cell gradually increases.
2. bacteriostasis efficacy
Lactobacillus reuteri TR02 and Lactobacillus reuteri TR02 is mixed with Candida albicanss culture fluid, is determined respectively
0th, 6,9,12, the OD values of 24h and pH value, as shown in figure 9, Lactobacillus reuteri TR02 has obvious antibacterial effect to Candida albicanss
Really, and the pH value of environment can substantially be reduced.
SEQUENCE LISTING
<110>Its beneficial health science academy（Zhenjiang）Company limited
<120>A kind of Lactobacillus reuteri and its application
<130> SC20161008001
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1490
<212> DNA
<213> Lactobacillus reuteri
<220>
<221> misc_feature
<222> (1)..(1490)
<400> 1
gggtacgcgg cggtgtgcta tacatgcaag tcgtacgcac tggcccaact gattgatggt 60
gcttgcacct gattgacgat ggattaccag tgagtggcgg acgggtgagt aacacgtagg 120
taacctgccc cggagcgggg gataacattt ggaaacagat gctaataccg cataacaaca 180
aaagccacat ggcttttgtt tgaaagatgg ctttggctat cactctggga tggacctgcg 240
gtgcattagc tagttggtaa ggtaacggct taccaaggcg atgatgcata gccgagttga 300
gagactgatc ggccacaatg gaactgagac acggtccata ctcctacggg aggcagcagt 360
agggaatctt ccacaatggg cgcaagcctg atggagcaac accgcgtgag tgaagaaggg 420
tttcggctcg taaagctctg ttgttggaga agaacgtgcg tgagagtaac tgttcacgca 480
gtgacggtat ccaaccagaa agtcacggct aactacgtgc cagcagccgc ggtaatacgt 540
aggtggcaag cgttatccgg atttattggg cgtaaagcga gcgcaggcgg ttgcttaggt 600
ctgatgtgaa agccttcggc ttaaccgaag aagtgcatcg gaaaccgggc gacttgagtg 660
cagaagagga cagtggaact ccatgtgtag cggtggaatg cgtagatata tggaagaaca 720
ccagtggcga aggcggctgt ctggtctgca actgacgctg aggctcgaaa gcatgggtag 780
cgaacaggat tagataccct ggtagtccat gccgtaaacg atgagtgcta ggtgttggag 840
ggtttccgcc cttcagtgcc ggagctaacg cattaagcac tccgcctggg gagtacgacc 900
gcaaggttga aactcaaagg aattgacggg ggcccgcaca agcggtggag catgtggttt 960
aattcgaagc tacgcgaaga accttaccag gtcttgacat cttgcgctaa ccttagagat 1020
aaggcgttcc cttcggggac gcaatgacag gtggtgcatg gtcgtcgtca gctcgtgtcg 1080
tgagatgttg ggttaagtcc cgcaacgagc gcaacccttg ttactagttg ccagcattaa 1140
gttgggcact ctagtgagac tgccggtgac aaaccggagg aaggtgggga cgacgtcaga 1200
tcatcatgcc ccttatgacc tgggctacac acgtgctaca atggacggta caacgagtcg 1260
caagctcgcg agagtaagct aatctcttaa agccgttctc agttcggact gtaggctgca 1320
actcgcctac acgaagtcgg aatcgctagt aatcgcggat cagcatgccg cggtgaatac 1380
gttcccgggc cttgtacaca ccgcccgtca caccatggga gtttgtaacg cccaaagtcg 1440
gtggcctaac ctttatggag ggagccgcct aaggcggaca gagactgggt 1490
Claims (4)
1. a kind of Lactobacillus reuteri (Lactobacillus reuteri) TR02, is deposited in China typical culture collection
The heart (abbreviation CCTCC), deposit number is：CCTCC No.M 2016546, preservation date are on October 10th, 2016.
2. application of the Lactobacillus reuteri described in claim 1 in antibacterials are prepared.
3. application of the Lactobacillus reuteri described in claim 1 in the medicine for preparing treatment gastroenteropathy.
4. application of the Lactobacillus reuteri described in claim 1 in the medicine for preparing treatment enteritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610937700.2A CN106520599A (en) | 2016-10-25 | 2016-10-25 | Lactobacillus reuteri and applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610937700.2A CN106520599A (en) | 2016-10-25 | 2016-10-25 | Lactobacillus reuteri and applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106520599A true CN106520599A (en) | 2017-03-22 |
Family
ID=58292639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610937700.2A Pending CN106520599A (en) | 2016-10-25 | 2016-10-25 | Lactobacillus reuteri and applications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106520599A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107974425A (en) * | 2017-12-25 | 2018-05-01 | 富乐顿生物工程科技（北京）有限公司 | Space lactobacillus reuteri Fullarton-9-79 and application |
| CN108004179A (en) * | 2017-12-29 | 2018-05-08 | 龙大食品集团有限公司 | The lactobacillus reuteri and application of one plant of tool probiotic properties and antagonism production enterotoxigenic Escherichia coli |
| CN110997897A (en) * | 2017-07-11 | 2020-04-10 | 李溢圭 | Oral pathogenic bacteria inhibiting composition comprising lactobacillus reuteri CS 132(KCTC11452BP) or culture thereof |
| CN113943687A (en) * | 2021-12-21 | 2022-01-18 | 山东中科嘉亿生物工程有限公司 | Lactobacillus reuteri JYLB-291 for improving ulcerative colitis and application thereof |
| CN116004446A (en) * | 2022-11-30 | 2023-04-25 | 天津小薇生物科技有限公司 | Luo Yishi lactobacillus LL029 for improving immunity and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102304489A (en) * | 2011-09-23 | 2012-01-04 | 北京龙科方舟生物工程技术中心 | Lactobacillus reuteri strain and application thereof |
| WO2013027087A1 (en) * | 2011-08-23 | 2013-02-28 | Compagnie Gervais Danone | A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection |
| CN105219683A (en) * | 2015-11-04 | 2016-01-06 | 广东省农业科学院动物科学研究所 | One strain has L. reuteri strain and the application thereof of prebiotic characteristics |
-
2016
- 2016-10-25 CN CN201610937700.2A patent/CN106520599A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013027087A1 (en) * | 2011-08-23 | 2013-02-28 | Compagnie Gervais Danone | A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection |
| CN102304489A (en) * | 2011-09-23 | 2012-01-04 | 北京龙科方舟生物工程技术中心 | Lactobacillus reuteri strain and application thereof |
| CN105219683A (en) * | 2015-11-04 | 2016-01-06 | 广东省农业科学院动物科学研究所 | One strain has L. reuteri strain and the application thereof of prebiotic characteristics |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110997897A (en) * | 2017-07-11 | 2020-04-10 | 李溢圭 | Oral pathogenic bacteria inhibiting composition comprising lactobacillus reuteri CS 132(KCTC11452BP) or culture thereof |
| CN107974425A (en) * | 2017-12-25 | 2018-05-01 | 富乐顿生物工程科技（北京）有限公司 | Space lactobacillus reuteri Fullarton-9-79 and application |
| CN107974425B (en) * | 2017-12-25 | 2019-08-30 | 富乐顿生物工程科技（北京）有限公司 | Space lactobacillus reuteri Fullarton-9-79 and application |
| CN108004179A (en) * | 2017-12-29 | 2018-05-08 | 龙大食品集团有限公司 | The lactobacillus reuteri and application of one plant of tool probiotic properties and antagonism production enterotoxigenic Escherichia coli |
| CN113943687A (en) * | 2021-12-21 | 2022-01-18 | 山东中科嘉亿生物工程有限公司 | Lactobacillus reuteri JYLB-291 for improving ulcerative colitis and application thereof |
| CN113943687B (en) * | 2021-12-21 | 2022-02-22 | 山东中科嘉亿生物工程有限公司 | Lactobacillus reuteri JYLB-291 for improving ulcerative colitis and application thereof |
| CN116004446A (en) * | 2022-11-30 | 2023-04-25 | 天津小薇生物科技有限公司 | Luo Yishi lactobacillus LL029 for improving immunity and application thereof |
| CN116004446B (en) * | 2022-11-30 | 2024-01-26 | 天津小薇生物科技有限公司 | Luo Yishi lactobacillus LL029 for improving immunity and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106520599A (en) | Lactobacillus reuteri and applications | |
| CN106520598A (en) | Lactobacillus rhamnosus and application | |
| CN104560820B (en) | VREF KQ2.6 and application | |
| TWI308591B (en) | Organism-culturing apparatus and organism-culturing method | |
| CN105132318B (en) | Lactobacillus plantarum Grx16 and its application | |
| CN104630083B (en) | A kind of Lactobacillus crispatus and its application in feminine care products | |
| CN108004187A (en) | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines | |
| CN106754470A (en) | The Lactobacillus rhamnosus in one plant of lacto source and its application | |
| CN103911306B (en) | Lactobacillus gasseri bacterial strain and application thereof | |
| CN110144304A (en) | Lactobacillus casei bacterial strain and its application | |
| CN111925961B (en) | Lactobacillus plantarum Lp2 and application thereof | |
| CN101314763A (en) | Short bifidobacteria with functions of anti-gastrointestinal tract pathogen, oxidation resistance and blood pressure reduction | |
| CN110669690B (en) | Lactobacillus plantarum strain for expressing quorum sensing signal molecule AI-2 and application thereof | |
| CN110577912A (en) | lactobacillus gasseri and application thereof in preparing fermented milk | |
| CN106497808A (en) | One plant of Lactobacillus salivarius that can be used to produce fermented feed for being isolated from Intestinum Sus domestica road | |
| CN104818230A (en) | Lactobacillus plantarum L01 having cholesterol degrading function and application thereof | |
| CN112094785A (en) | Bifidobacterium animalis as well as preparation and application thereof | |
| CN107325997A (en) | Bifidobacterium longum and its application with cephalo resistance and high expression Sir2 albumen | |
| CN117143767B (en) | Breast milk-derived fermented lactobacillus mucilaginosus MSJK capable of regulating intestinal flora and application thereof | |
| CN113736683A (en) | Streptococcus thermophilus for inhibiting helicobacter pylori and application thereof | |
| CN106834197B (en) | A kind of abductive approach of lactobacillus VBNC state | |
| CN103911309B (en) | Lactobacillus gasseri bacterial strain and application thereof | |
| CN111040959A (en) | Grass carp source lactic acid bacteria with specific pathogenic microorganism antagonistic capability and application thereof | |
| CN104877940B (en) | One plant of streptococcus thermophilus | |
| CN117844692B (en) | Lactobacillus taiwan and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |